Optimising RSV sample handling and laboratory workflows to support faster, more efficient clinical trial delivery.
Immuron Limited announced the submission of the Clinical Study Report for its Phase 2 clinical trial of Travelan® (IMM-124E) to the FDA, which demonstrated statistically significant immunological and ...
Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback